Home Companies Catalysts Deep Dives
Ilaris canakinumab APPROVED
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaImmunology
Launch2009-06-17
US LOE2024-06-17
Peak Sales Est$1500M
Formulations[{"id":"ilaris-sc","doses":"150mg/mL vial","route":"SC","setting":"HCP_ADMINISTERED","frequency":"Ev
Companies
NVS (ORIGINATOR)100%
Mechanism: IL-1β inhibitor
Expert: Monoclonal antibody targeting interleukin-1 beta
Everyday: Blocks an inflammatory protein that causes fever and inflammation
Targets: ["IL-1B"]
Revenue History
PeriodRevenue ($M)
2024$920M
2025$980M
Programs (2)
IndicationStageKey StudyRegional Status
CAPSAPPROVEDCAPS pivotal[{"stage":"APPROVED","region":"US","approval_date":"2009-06-17"},{"stage":"APPRO
SJIAAPPROVEDSJIA pivotal[{"stage":"APPROVED","region":"US","approval_date":"2013-05-10"}]
Notes
IL-1β inhibitor. Rare auto-inflammatory diseases. Niche but durable.
Data from Supabase · Updated 2026-03-24